Midazolam as a potential CYP3A phenotyping probe for cabazitaxel metabolism.

Midazolam as a potential CYP3A phenotyping probe for cabazitaxel metabolism. - MAILMAN-study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON37899

Enrollment

Registered

2012-06-01

Start date

2013-01-14

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer - bone metastases

Interventions

All men will be administered a single intravenous dose of midazolam (2.5mg) before regular treatment with cabazitaxel. After midazolam and after cabazitaxel administration blood samples will be coll

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Metastasized hormone refractory prostate cancer. Progression of disease during or after treatment with docetaxel.

Exclusion criteria

Exclusion criteria: Severe dyspnea Myasthenia Gravis Sleep apnea syndrome. Severe hepatic dysfunction Age 80 years and older

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics of midazolam and cabazitaxel.	—

Secondary

Measure	Time frame
Does not apply	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)